PL2638042T3 - Antagoniści receptorów CGRP w postaci piperydynonokarboksyamidu azaindanu - Google Patents

Antagoniści receptorów CGRP w postaci piperydynonokarboksyamidu azaindanu

Info

Publication number
PL2638042T3
PL2638042T3 PL11787987T PL11787987T PL2638042T3 PL 2638042 T3 PL2638042 T3 PL 2638042T3 PL 11787987 T PL11787987 T PL 11787987T PL 11787987 T PL11787987 T PL 11787987T PL 2638042 T3 PL2638042 T3 PL 2638042T3
Authority
PL
Poland
Prior art keywords
azaindane
receptor antagonists
cgrp receptor
piperidinone carboxamide
piperidinone
Prior art date
Application number
PL11787987T
Other languages
English (en)
Inventor
Ian M Bell
Mark E Fraley
Steven N Gallicchio
Anthony Ginnetti
Helen J Mitchell
Daniel V Paone
Donnette D Staas
Cheng Wang
C Blair Zartman
Heather E Stevenson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2638042T3 publication Critical patent/PL2638042T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11787987T 2010-11-12 2011-11-10 Antagoniści receptorów CGRP w postaci piperydynonokarboksyamidu azaindanu PL2638042T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41307710P 2010-11-12 2010-11-12
US201061425034P 2010-12-20 2010-12-20
EP11787987.4A EP2638042B1 (en) 2010-11-12 2011-11-10 Piperidinone carboxamide azaindane cgrp receptor antagonists
PCT/US2011/060081 WO2012064910A1 (en) 2010-11-12 2011-11-10 Piperidinone carboxamide azaindane cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
PL2638042T3 true PL2638042T3 (pl) 2015-03-31

Family

ID=45034191

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14185954T PL2821407T3 (pl) 2010-11-12 2011-11-10 Antagoniści receptorów cgrp w postaci piperydynonokarboksyamidu azaindanu
PL11787987T PL2638042T3 (pl) 2010-11-12 2011-11-10 Antagoniści receptorów CGRP w postaci piperydynonokarboksyamidu azaindanu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14185954T PL2821407T3 (pl) 2010-11-12 2011-11-10 Antagoniści receptorów cgrp w postaci piperydynonokarboksyamidu azaindanu

Country Status (43)

Country Link
US (8) US8754096B2 (pl)
EP (2) EP2638042B1 (pl)
JP (1) JP5642883B2 (pl)
KR (1) KR101537877B1 (pl)
CN (1) CN103328478B (pl)
AR (1) AR083831A1 (pl)
AU (1) AU2011326454B2 (pl)
BR (1) BR112013011448B8 (pl)
CA (1) CA2817100C (pl)
CL (1) CL2013001289A1 (pl)
CO (1) CO6801723A2 (pl)
CR (1) CR20130214A (pl)
CY (2) CY1118362T1 (pl)
DK (2) DK2638042T3 (pl)
DO (1) DOP2013000103A (pl)
EA (1) EA022850B1 (pl)
EC (1) ECSP13012676A (pl)
ES (2) ES2604827T3 (pl)
FI (1) FIC20230034I1 (pl)
FR (1) FR23C1039I2 (pl)
GT (1) GT201300122A (pl)
HR (2) HRP20141108T1 (pl)
HU (2) HUE031010T2 (pl)
IL (1) IL225978A (pl)
LT (2) LT2821407T (pl)
LU (1) LUC00321I2 (pl)
MA (1) MA34650B1 (pl)
ME (2) ME02552B (pl)
MX (1) MX2013005246A (pl)
MY (1) MY165113A (pl)
NI (1) NI201300043A (pl)
NL (1) NL301248I2 (pl)
NO (1) NO2023040I1 (pl)
NZ (1) NZ610468A (pl)
PE (1) PE20140240A1 (pl)
PH (1) PH12013500958A1 (pl)
PL (2) PL2821407T3 (pl)
PT (2) PT2821407T (pl)
RS (2) RS55416B1 (pl)
SG (2) SG10201509335VA (pl)
SI (2) SI2821407T1 (pl)
TW (3) TWI522355B (pl)
WO (1) WO2012064910A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR20220164616A (ko) * 2012-03-14 2022-12-13 머크 샤프 앤드 돔 코포레이션 Cgrp 수용체 길항제의 제조 방법
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
RU2690006C2 (ru) * 2013-09-16 2019-05-30 Мерк Шарп И Доум Корп. Композиции антагонистов рецепторов cgrp
EP3102564A4 (en) * 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908420D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
CN110787163B (zh) * 2019-12-05 2020-06-02 河北医科大学第二医院 一种用于神经保护和促进神经再生的药物组合物及其制剂
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
US20250136602A1 (en) * 2021-12-20 2025-05-01 Msn Laboratories Private Limited, F&D Center Process for the preparation of a pure amorphous form of ubrogepant
EP4516793A4 (en) * 2022-04-29 2025-08-27 Brise Pharmaceuticals Co Ltd PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, ITS PREPARATION PROCESS AND USE
WO2024081718A1 (en) 2022-10-11 2024-04-18 Allergan Pharmaceuticals International Limited Cgrp receptor antagonist for the treatment of migraine
WO2024134683A1 (en) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of intermediate compounds used in the treatment of migraine
WO2024218790A1 (en) * 2023-04-15 2024-10-24 Msn Laboratories Private Limited, R&D Center A pharmaceutical composition of ubrogepant and their process for the preparation of solid dosage form for treating migraine
CN118834160B (zh) * 2023-04-23 2025-12-19 中国医学科学院药物研究所 Ubrelvy关键手性内酰胺中间体及其衍生物的不对称合成方法
CN119431222B (zh) * 2024-11-04 2025-10-17 杭州澳赛诺生物科技有限公司 一种不对称合成乌布吉泮手性中间体的方法
CN119350337A (zh) * 2024-12-24 2025-01-24 药康众拓(北京)医药科技有限公司 一类氘代哌啶酮酸酰胺氮杂茚满类cgrp抑制剂药物及用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU2004222378B2 (en) 2003-03-14 2008-08-14 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin CGRP receptor antagonists
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
ATE464305T1 (de) * 2004-09-13 2010-04-15 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CA2599925A1 (en) * 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
BRPI0711352A2 (pt) 2006-05-09 2011-09-27 Merck & Co Inc composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
EP2161996B1 (en) 2007-06-05 2014-07-16 Merck Sharp & Dohme Corp. Heterocyclic carboxamide cgrp receptor antagonists
WO2009065922A2 (de) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
WO2012064911A1 (en) * 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US9067941B2 (en) * 2010-12-22 2015-06-30 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide CGRP receptor antagonists
WO2012087777A1 (en) * 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide cgrp receptor antagonists
EP2685826B1 (en) * 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9109209B2 (en) * 2011-09-08 2015-08-18 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
AU2013232191B2 (en) * 2012-03-14 2017-03-30 Merck Sharp & Dohme Llc Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
WO2013169574A2 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
US9227973B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Pyridine CGRP receptor antagonists
US9174989B2 (en) * 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
EP2846799B1 (en) * 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
RU2690006C2 (ru) * 2013-09-16 2019-05-30 Мерк Шарп И Доум Корп. Композиции антагонистов рецепторов cgrp
EP3102564A4 (en) * 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
EP3110427A4 (en) * 2014-02-24 2018-05-30 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound

Also Published As

Publication number Publication date
MX2013005246A (es) 2013-05-28
MA34650B1 (fr) 2013-11-02
US20170027925A1 (en) 2017-02-02
HRP20161641T1 (hr) 2017-01-13
EP2638042A1 (en) 2013-09-18
HUE031010T2 (en) 2017-06-28
US20180092900A1 (en) 2018-04-05
DOP2013000103A (es) 2013-10-15
PE20140240A1 (es) 2014-03-14
DK2638042T3 (en) 2015-01-05
FR23C1039I2 (fr) 2024-11-15
JP2013542260A (ja) 2013-11-21
GT201300122A (es) 2015-06-02
US10272077B2 (en) 2019-04-30
TWI487706B (zh) 2015-06-11
US20120122900A1 (en) 2012-05-17
US9833448B2 (en) 2017-12-05
EP2821407B1 (en) 2016-09-21
SG10201509335VA (en) 2015-12-30
CA2817100C (en) 2015-09-29
US8481556B2 (en) 2013-07-09
EA201390683A1 (ru) 2013-09-30
CA2817100A1 (en) 2012-05-18
LTPA2023532I1 (pl) 2023-11-27
IL225978A (en) 2015-11-30
ME02552B (me) 2017-02-20
DK2821407T3 (da) 2017-01-02
TWI501968B (zh) 2015-10-01
CY1118362T1 (el) 2017-06-28
PT2821407T (pt) 2016-12-06
SI2821407T1 (sl) 2016-12-30
CL2013001289A1 (es) 2013-08-09
NL301248I2 (nl) 2023-11-20
US8912210B2 (en) 2014-12-16
US20120122899A1 (en) 2012-05-17
NI201300043A (es) 2013-07-01
CO6801723A2 (es) 2013-11-29
CY2023022I1 (el) 2024-02-16
TW201520214A (zh) 2015-06-01
EP2821407A1 (en) 2015-01-07
LUC00321I2 (pl) 2026-02-02
WO2012064910A1 (en) 2012-05-18
KR20130087037A (ko) 2013-08-05
MY165113A (en) 2018-02-28
TWI522355B (zh) 2016-02-21
PL2821407T3 (pl) 2017-04-28
SG190137A1 (en) 2013-07-31
SI2638042T1 (sl) 2015-01-30
US20190275024A1 (en) 2019-09-12
RS53610B1 (sr) 2015-04-30
JP5642883B2 (ja) 2014-12-17
ES2525021T3 (es) 2014-12-16
BR112013011448A2 (pt) 2016-08-09
NZ610468A (en) 2015-06-26
TW201520213A (zh) 2015-06-01
US20150005330A1 (en) 2015-01-01
LTC2638042I2 (pl) 2025-07-10
AU2011326454B2 (en) 2015-05-21
RS55416B1 (sr) 2017-04-28
US20210008055A1 (en) 2021-01-14
ES2604827T3 (es) 2017-03-09
BR112013011448B1 (pt) 2021-06-01
PT2638042E (pt) 2014-12-09
US9499545B2 (en) 2016-11-22
PH12013500958A1 (en) 2013-07-15
HUS2300037I1 (hu) 2023-11-28
FR23C1039I1 (fr) 2023-12-08
IL225978A0 (en) 2013-06-27
HRP20141108T1 (hr) 2015-01-16
LT2821407T (lt) 2016-12-12
AU2011326454A1 (en) 2013-05-23
BR112013011448B8 (pt) 2022-03-29
US20120122911A1 (en) 2012-05-17
HK1200163A1 (en) 2015-07-31
NO2023040I1 (no) 2023-10-20
TW201305165A (zh) 2013-02-01
ME01922B (me) 2015-05-20
EA022850B1 (ru) 2016-03-31
ECSP13012676A (es) 2013-08-30
US8754096B2 (en) 2014-06-17
AR083831A1 (es) 2013-03-27
CR20130214A (es) 2013-06-28
EP2638042B1 (en) 2014-09-24
CN103328478A (zh) 2013-09-25
KR101537877B1 (ko) 2015-07-17
CN103328478B (zh) 2015-10-07
FIC20230034I1 (fi) 2023-11-10

Similar Documents

Publication Publication Date Title
CY2023022I1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
HUS2200033I1 (hu) CGRP receptor antagonisták
EP2911675A4 (en) 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
SMT201600078B (it) Antagonista del recettore per cgrp
IL239604A0 (en) Anti-vegf antibodies and their uses
EP2585064A4 (en) C5aR Antagonist
EP2908812A4 (en) 2-pyridyloxy, 3-ESTER-4-NITRILOREXIN receptor antagonists
EP2637656A4 (en) PIPERIDINONE CARBOXAMIDINDANES AS CGRP RECEPTOR ANTAGONISTS
EP2934516A4 (en) 3 ESTER 4 SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
PL2513093T3 (pl) Nowi antagoniści receptora CCR2 i ich zastosowanie
IL232949A (en) Methods and Compounds Used in the Synthesis of Orxin-2 Antagonist Receptor
IL226491A0 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
EP2381778A4 (en) C5aR Antagonist
EP2438041A4 (en) PYRAZINE-carboxamide-orexin receptor Antagonist
EP2709991A4 (en) USE OF CXCR4 ANTAGONISTS
EP2685826A4 (en) PIPERIDINONCARBOXAMID-spiro hydantoin-CGRP receptor antagonists
DK3312169T3 (da) 5-ht3 receptorantagonister
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
SMT201500296B (it) Antagonisti del recettore trpm8
EP2654421A4 (en) CONDENSED HETEROCYCLIC INDAN CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS
PL2793883T3 (pl) Antagoniści trpm8
EP2771346A4 (en) ISOXAZOLOPYRIDIN-orexin
EP2458991A4 (en) RADIOACTIVELY MARKED CGRP ANTAGONISTS
EP2539706A4 (en) ARYLPIPERAZON-OPIOID RECEPTOR ANTAGONISTS
EP2341919A4 (en) CGRP RECEPTOR ANTAGONISTS